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Introduction
Non-alcoholic fatty liver disease (NAFLD) is one of the 
most common liver diseases of adults and is defined 
as evidence of hepatic steatosis, either by imaging or 
histology (1). The prevalence of this disease is 20%-30% 
in the general populations of Western countries. NAFLD 
is the most common predisposing factor for liver cirrhosis 
(2). Epidemiologic studies demonstrated prevalence of 
21.5% for NAFLD in one group of Iranian adults and 7.1% 
in Iranian children (3). However, the prevalence of fatty 
liver is also enhancing in these age groups by increasing 
the incidence of obesity in children and adolescents. Due 
to complications of NAFLD, the treatment of this disease 
is essential (4,5).
Several treatment options have been recommended 
for NAFLD, which have been reviewed elsewhere (6). 
The beneficial effect of silymarin was observed on 
alcoholic liver steatosis, which supports its efficacy in 
treatment of NAFLD. The positive effects of milk thistle 
(silymarin) were shown in terms of anti-inflammatory, 
antifibrotic and cytoprotective properties in liver (7). 
In a placebo-controlled trial in patients with NAFLD 
silymarin significantly improved biochemical markers of 
the patients (8). The beneficial effect of crude extract of 
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Introduction: Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases 
of adults and its prevalence is increasing in children and adolescents. It is the most predisposing 
factor for liver cirrhosis. Due to complications of NAFLD, the treatment of this disease is essential. 
Since silymarin is recommended for adults recently, the effect of this herbal drug on children and 
adolescents was evaluated for treatment of NAFLD in children. 
Methods: This is a clinical trial study, which was done in Shahrekord University of Medical 
Science in 2012-2013 on 5-16 years old children with NAFLD. The patients were randomly divided 
into two groups containing 20 patients in each group. Silymarin tablets were administered for 12 
weeks in case group and changing life style including exercise was advised in both groups. Liver 
sonographay and liver function tests (LFTs) were done after 12 weeks. 
Results: Patients with higher grade of fatty liver were developed lower grade of fatty liver 
during intervention in case group based on sonography after 12 weeks (P = 0.001). Meanwhile, 
no significant changes were observed in control group (P = 0.35). Liver enzymes (alanine 
aminotransferase [ALT] and aspartate transaminase [AST]) (P = 0.001, P = 0.025, respectively) and 
triglyceride (TG) levels (P = 0.043) were improved significantly but low-density lipoprotein (LDL) 
and high-density lipoprotein (HDL) did not change during intervention in case group. 
Conclusion: Silymarin can improve fatty infiltration of liver and liver function in children and 
adolescents.
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Silybum marianum with high polyphenolic content was 
elucidated on one group of nonalcoholic steatohepatits 
patients (9). It was indicated that silymarin is superior to 
metformin and pioglitazone on improvement of fatty liver 
of adults (10).
Silymarin is extract of thistle herb seeds that is orally 
absorbed and excreted into the bile as sulfate-conjugate. It 
can also be used as a supplement for normal functioning 
of the liver because of its antioxidant property, lipid 
lowering and anti-inflammatory effects (11-13). It also 
can increase the detoxifying effect of liver by increment of 
glucuronidation activity and avoiding decrease glucuronic 
acid reserve of liver (14). The anti-inflammatory 
effect of silymarin is due to inhibiting leukotriene and 
prostaglandin synthesis, inhibit Kupffer cells, stabilizing 
mast cells and avoiding neutrophil migration in human 
body. This herbal medication can also increase hepatocyte 
protein synthesis, which needs for repairing liver tissue, 
slowing fibrosis process and even improvement of liver 
fibrosis (7). 
There is no definite treatment for NAFLD till now so 
finding an effective treatment for this disease can prevent 
cirrhosis and end stage liver disease. Moreover, there is no 
study about silymarin effect on NAFLD of children. Due to 
the importance of NAFLD and its potential complications 
the purpose of this work is to investigate about this herbal 
drug on recovery of liver function tests and sonographic 
changes of these patients.
Patients and Methods 
Subjects and protocol
This is a cross sectional, randomized and double blind 
clinical trial, which was done in out-patient departments 
of Shahrekord University of Medical Sciences from 
February 2012 till March 2013. This study was confirmed 
by Ethical committee of Shahrekord University of 
Medical Science and registered in IRCT website (code: 
IRCT2016080614882N4). The trial was conducted 
on 40 children and adolescents (5-16 years old) with 
NAFLD. These patients were referred from pediatricians 
and endocrinologists to pediatric gastroenterology and 
hepatology clinic because of their obesity or overweight 
that sonography and/or liver enzymes were suspicious to 
fatty liver. The diagnosis of NAFLD was based on history 
taking and precise physical examinations performed by 
the same pediatric, gastroenterologist, hepatologist, as 
well as sonography and laboratory evidences in favor of 
fatty liver.
NAFLD was considered as sonographic evidence of fatty 
infiltration of liver (G1-3) with or without abnormal 
liver function tests (LFTs) in non-alcoholic subjects (15). 
Other causes of fatty liver and abnormal LFT including 
Wilson disease, viral hepatitis, auto immune hepatitis, 
juvenile hemochromatosis, and other underlying diseases 
were excluded. Patients were also excluded in presence 
of evidence of cirrhosis, advanced liver disease, any 
underlying liver disease, diabetes mellitus, metabolic 
syndromes and previous treatment with other medications. 
Forty children and adolescent were registered for the 
study with voluntary basis. They were divided to 2 groups, 
randomly.
Study design
Instruments with the following specifications were 
used to study different parameters: 1) Weight (Beurer 
digital GS34 Bargraph); 2) Height (wall meter, Seca 206 
with 1mm accuracy); 3) Body mass index, BMI 4) Liver 
enzymes (Pars Azmoon kit); 5) Liver sonography (using 
an ultrasound multi-frequency curvilinear 3.5-5 MHz 
probe by Siemens Company, Sonoline G50 series, model 
number 7474922).
Period of treatment was 12 weeks. Patients who had 
inclusion criteria were assigned consecutive numbers. For 
odd numbers, silymarin and changing life style including 
exercise were considered. Meanwhile, only life style 
changes and exercise were considered for even numbers. 
The recommended 150-250 min/wk, walking according 
to American College of Sport Medicine and low fat as 
well as low carbohydrate diet, was used (16). Silymarin 70 
and 140 mg tablets with brand name of Livergol (Goldaru 
company, Iran) (with dosage of 5 mg/kg/d, divided 3 dose 
with meal) were used.
Patients were not allowed to use other drugs for weight 
reduction or lipid lowering purposes. The patients of two 
groups had not significant difference in demographic 
variables including age, sex and BMI. Parents of children 
and adolescents with NAFLD provided written informed 
consent for voluntary arrival.
Follow up
Weight and BMI were measured again after the 12-week 
period. The sonography was o done again by the same 
sonographist. LFTs and lipid profiles were checked in 
the same laboratory. Patients were evaluated each month 
for compliance to intervention, drug consumption and 
adverse effects of medication (allergic reaction, GI upset, 
loose stool).
Data analysis
Data analysis was done with SPSS software version 20 
(IBM, Armonk, NY).
Results
Forty patients with NAFLD participated in the study and 
were divided into two groups; case and control. All patients 
completed the intervention. Anthropometric parameters 
of the two groups are shown in Table 1. Laboratory data 
of the two groups before and after the intervention are 
shown in Table 2. Variables of NAFLD were evaluated at 
the end of the intervention.
Grade of fatty liver
In the case and control groups, 10 patients had fatty liver 
grade 1 (50% vs. 50%), 8 and 10 patients, respectively, grade 
2 (40% vs. 50%), and only in the case group, two patients 
(10%) grade 3. No statistically significant differences were 
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observed between the two groups (P = 0.44). Table 3 shows 
the results after the treatment; 15 patients in the case 
group (75%) and 11 patients (55%) in the control group 
had grade 1 fatty liver. Thus, the number of the patients 
with fatty liver grade 1 increased from 10 to 15 patients 
in the case group. Therefore, some patients with higher 
grade of fatty liver developed lower grade of fatty liver 
after the intervention based on sonography (P = 0.001). 
Meanwhile, as seen in Table 3, no significant changes were 
observed in the control group (P = 0.35). 
Aspartate transaminase level
According to Table 2, no statistically significant difference 
in aspartate transaminase (AST) level was observed before 
and after the treatment in the control group. Meanwhile, 
significant differences were observed in the intervention 
group (P = 0.025).
Alanine aminotransferase level
At the beginning of the study, there was not statistically 
significant difference between the two groups (P = 0.09). 
As shown in Table 2, level of alanine aminotransferase 
(ALT) decreased significantly in silymarin group 
(P = 0.015) at completion of the treatment. In contrast to 
silymarin group, no significant changes were observed in 
the control group (P = 0.02). 
Triglyceride level
Mean triglyceride (TG) levels were statistically different 
between the two groups before the intervention 
(P = 0.034). TG levels also decreased statistically in both 
silymarin (P = 0.043) and control (P = 0.040) groups at 
completion of the intervention. As seen in Table 2, low-
density lipoprotein (LDL) cholesterol and high-density 
lipoprotein (HDL) cholesterol levels were not significantly 
different before and after the intervention in both groups.
Body mass index
BMI did not change significantly before and after the 
treatment (25.8 ± 4.1 and 25.2 ± 3.8, respectively).
Discussion
NAFLD refers to a wide spectrum of diseases, including 
augmented fat content in the liver (steatosis), inflammatory 
change, non-alcoholic steatohepatitis (NASH), and 
potentially fibrosis and cirrhosis (17). It is one of the 
most prevalent liver diseases among adults and the 
most common predisposing factor for liver cirrhosis (2). 
However, the prevalence of fatty liver in these age groups 
is increasing by rising obesity in children and adolescents. 
NAFLD is due to chronic liver disease, cirrhosis, and 
ESRD. NAFLD is now recognized as a component of 
metabolic syndrome, including hyperlipidemia, glucose 
intolerance, hyperinsulinism, and obesity. Risk and 
severity of NAFLD are increased through a number of 
metabolic syndrome components (17). Treatment of 
NAFLD includes appropriate weight loss, elimination of 
objective drugs and toxins, control of metabolic disorders, 
such as diabetes and hyperlipidemia. Several studies have 
been conducted on diet and exercise as well as some 
medications with inconsistent results (18).
The present study confirmed the effect of silymarin on 
improvement of NAFLD in the children and adolescents. 
Unlike similar studies conducted in Iran and other 
countries on adults, this research was conducted on 
children. Our findings confirm that silymarin can exert 
Table 1.  Anthropometric  measurements
Variables  Sylimarin group (mean ± SD) Placebo group (mean ± SD) Difference P valuea
Age (y)a 11.8 ± 3 10.5 ± 3.2 1.3 ± 0.2 0.2
Weight (kg)a 61.8 ± 16.7 60.3 ± 13.6 1.5 ± 3.1 0.76
BMI (kg/m2)a 25.8 ± 4.1 24.3 ± 4.5 1.5 ± 0.4 0.29
Height (cm) 153.1 ± 13 157 ± 8.5 3.9 ± 4.5 0.27
a P < 0.05 is statistically significant.                       
Table 2. Different clinical parameters in case and control groupsa
ALT (U/L) AST (U/L) TG (mg/dL) LDL (mg/dL) HDL (mg/dL) 
Before After P Before After P Before After P Before After P Before After P
Silymarin 47.3±5.4 36.4±6.6 0.015 49.1±2.2 31.5±1.3 0.025 203.7± 5.7 198.8± 13.8 0.043 121.8±4.4 118.4± 11.4 0.1 45.5±9 50.7±13.4 0.11
P 0.09 0.043 0.43 0.003 0.04 0.034 0.14 0.34 0.99 0.98
Abbreviations: AST, aspartate aminotransferase; ALT, alanin aminotransferase; LDL, Low-density lipoprotein; HDL, High-density lipoprotein; TG, 
triglyceride.
a Normal ranges: AST & ALT<40 U/L, TG < 150 mg/dL, LDL < 100 mg/dL, HDL >60 mg/dL. 
Table 3. Grades of fatty liver




No. (%) P value
Before 
1 10 (50) 10 (50) 
0.54  2 8 (40) 10 (50) 
3 2 (10) 0 (0)
After 
1 15 (75) 11 (55) 
0.44 2 2 (10) 5 (25) 
 3 3 (15) 4 (20) 
P value  0.001 0.35 
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beneficial effect on improvement of NAFLD in children 
aged 5-16 years. Hashemi et al in a placebo-control study 
suggested that silymarin could be significantly effective 
on biochemical improvement and in decreasing the ALT 
and AST levels in patients with NASH because of its 
antioxidant property (8).
Hajiani et al in a comparative study between silymarin 
and vitamin E concluded that both medications could 
improve sonographic findings and liver enzymes because 
of antioxidant effect of vitamin E and antioxidant, anti-
inflammatory, and hepatocyte membrane-stabilizing 
actions of silymarin (19). Mitochondria are the main 
sites of lipids metabolism and oxidative phosphorylation 
in the liver. Oxidative stress can cause mitochondrial 
dysfunction in NASH. The excess of free fatty acids 
increases mitochondrial H2O2 production. Then, this 
compound oxidizes mitochondrial membranes that 
regulate the activity of uncoupling protein 2 and carnitine 
palmitoyl transferase-1 (20). Silymarin with antioxidant 
properties can be effective in prevention and treatment of 
this disease.
Cacciapuoti et al showed that silymarin administration for 
6 months caused significant reduction in liver steatosis, 
according to sonography, and liver enzymes (AST and 
ALT) (21). In our study, use of silymarin for three months 
led to optimal results in the light of sonographic findings 
and liver enzymes. It seems that use of silymarin for longer 
periods can lead to more optimal findings.
It has been shown that silymarin exerts therapeutic effects 
on markers of NAFLD in adults (10). Silymarin can reduce 
serum cholesterol and TG as well (8). In our study, TG 
levels of the patients significantly decreased but no change 
was observed in LDL and HDL cholesterol. The patients in 
the present study had slightly abnormal cholesterol levels 
but strikingly high TG levels before the treatment. This 
may be due to differences in dietary regimen or eating 
habits between adults and children. 
Based on the findings, 50% of the patients had grade 1 
fatty liver before silymarin treatment in the intervention 
group. This figure increased to 75% after the treatment. In 
the control group, 50% and 55% of the patients had grade 
1 fatty liver before and after liver treatment, respectively. 
More clearly, silymarin could significantly decrease the 
grade of fatty liver in terms of physical activity alone. 
There  was no significant change in BMI after 12 weeks, 
which is consistent with another study (10). Therefore, 
longer treatments are needed to decrease BMI. Studies 
on children with longer treatments, which have already 
done on adults, can complement the available evidence 
and help draw more documented conclusions about 
silymarin effect on fatty liver in children. The results of 
this study show that silymarin is an effective herbal drug 
with few adverse effects and relatively good tolerance. 
Since a relatively small number of cases were investigated 
in this study because of lower prevalence of this disease in 
children compared to adults and the duration of the study 
(3 months) was not long enough, the results of the current 
work can be complemented by the study of similar cases 
in different countries. 
Conclusion 
This study confirmed that silymarin could improve 
biochemical and sonographic indices of NAFLD in 
children and adolescents. 
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